

PEPTIDE
THERAPEUTICS
SYMPOSIUM

By invitation only

2nd Annual Peptide Therapeutics Symposium
Saturday • **November 10th, 2007** • 7 AM – 5 PM
Hilton La Jolla Torrey Pines, **La Jolla, CA**
www.peptidetherapeutics.org

Sponsored by



Managed by



Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.

The company was founded in 1987 on the discovery of a hormone, amylin, produced by the same beta cells of the pancreas that make insulin. Since then, Amylin has built a strong foundation on research and development. Amylin's scientists are primarily focused on investigating the potential utility of new peptide hormone candidates. The company has amassed significant research and clinical expertise in metabolic medicine including the areas of diabetes, obesity and cardiovascular disease.

By "Challenging Science," Amylin challenges conventional thinking to create innovative approaches to the discovery, development and commercialization of novel therapies for metabolic diseases. Amylin's approach and dedication are rooted in the belief that they will be "Changing Lives" for millions of people - not only with the drugs currently in late-stage development, but also with their pipeline of future therapies.

Ferring Pharmaceuticals is a research-driven biopharmaceutical company identifying, developing and marketing innovative products in the fields of infertility, obstetrics, urology, gastroenterology, endocrinology and osteoarthritis.

With over 2500 employees worldwide, Ferring has a global presence, operating subsidiaries in over 40 countries and making its products available to patients in more than 70 countries.

Ferring research and development centers are located in San Diego, USA; Chilworth, UK; Copenhagen, Denmark; Saint-Prex, Switzerland; and Beer Tuvia, Israel. Ferring expertise encompasses peptide therapeutics, small molecule peptide/hormone mimetics, protease inhibitors and recombinant proteins.

Ferring Research Institute, Inc. was established in San Diego in 1996 as the company's center of excellence for peptide research, building upon Ferring's long-standing expertise in peptide therapeutics and commitment to provide "Medicine on the body's own terms."

Proudly representing the Southern California life sciences communities, **BIOCOM** has become the largest regional life sciences association in the world representing more than 550 member companies. Highly focused on the success of its members and the Southern life sciences community, BIOCOM consistently creates value through its programs and relevant member benefits.

Peptides.net is the major information portal providing a free, essential resource for all those involved in peptide research. Researchers and business leaders are kept up-to-date on the latest news and new products in this area, and also have access to exclusive presentations, specialist supplier listings, events, posters presentations, useful links and much more.

CONNECT is a non-profit organization dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego. Since 1985, CONNECT has assisted in the formation and development of over 1,200 companies and is widely regarded as the nation's most successful regional program linking inventors and entrepreneurs with the resources they need for success. Its programs include: Springboard, Venture Roundtable, Frontiers in Science and Technology, FrameWorks, and Connect with CONNECT; affiliate programs with The Center for Commercialization of Advanced Technology (CCAT), Tech Coast Angels (TCA), and MIT Enterprise Forum (MITEF); and its awards and recognition programs, Hall of Fame, and The Most Innovative New Products (MIP) Awards.

To contact CONNECT:
hgarrett@connect.org
858.964.1302



Be inspired!

Dear Speakers and Delegates,

On behalf of Amylin Pharmaceuticals and Ferring Research Institute, in partnership with CONNECT, we welcome you to the second annual Peptide Therapeutics Symposium at the Hilton La Jolla Torrey Pines in San Diego.

Illustrating the increasing scientific interest in peptide hormone systems and their therapeutic applications, this unique annual event brings together scientists from academia, biotech and pharmaceutical industry for a day of high quality exchange.

The program features a panel of distinguished speakers and leaders in peptide research and it will highlight recent successes, share new exciting research avenues and provide a broad perspective on the state of the art in the field.

Wishing you enjoyable and productive interactions with your peers, we hope that the meeting will inspire you and increase interest in this exciting area of discovery and research.

With kind regards,

David Maggs, M.D.


Vice President, Medical Affairs
Amylin Pharmaceuticals

Pierre Rivière, Ph.D.

Managing Director & Vice President, Research
Ferring Research Institute

Schedule of Events

Register online at
www.peptidetherapeutics.org



Introduction

- 7:00 a.m. Registration Opens
- 7:00-7:45 a.m. Breakfast
- 8:00-8:15 a.m. Welcome
David Maggs, M.D., *Amylin Pharmaceuticals*
- 8:15-8:45 a.m. Amylin: One Score Year and Then
Alain Baron, M.D., *Amylin Pharmaceuticals*



Discovery to Clinical Drug Candidate

- 8:45-9:30 a.m. Building, Understanding and Leveraging a Peptide Library
Michael Hanley, Ph.D., *Amylin Pharmaceuticals*
- 9:30-10:15 a.m. Application of Chemical Biotechnology
to the Optimization of Protein Therapeutics
Richard Dimarchi, Ph.D., *Indiana University*
- 10:15-10:30 a.m. Coffee Break

Into the Clinic

- 10:30-11:15 a.m. Degarelix: a Novel GnRH Antagonist
for the Treatment of Prostate Cancer
Per Cantor, M.D., Ph.D., *Ferring Pharmaceuticals*
- 11:15-Noon KL-4 Surfactant© Form to Function
Charles Cochran, M.D., *The Scripps Research Institute*





Noon-12:45 p.m. Lunch

Into the Market

12:45-13:30 p.m. **The Commercialization of Fuzeon® API**
Brad DeHoff, Ph.D., *Roche Colorado Corporation*

13:30-14:15 p.m. **The Beta Cell Hormone Amylin:
Discovery and Clinical Application**
Andrew Young, M.D., Ph.D., *Amylin Pharmaceuticals*

14:15-14:30 p.m. Coffee Break

Peptide Systems for the Future

14:30-15:15 p.m. **“Y not Y2 and Y4 Peptide Agonists for Treatment
of Diabetes and Obesity?”**
Thue Schwartz, M.D., D.M.Sci., *7TM Pharma
& University of Copenhagen*

15:15-16:00 p.m. **Oxyntomodulin or Products of the PYY Preproglucagon Gene**
Steve Bloom, M.D., *Imperial College, London*

16:00-16:45 p.m. **The Therapeutic Opportunities for Leptin:
An Ongoing Play in Three or More Acts**
Jeff Friedman, M.D., Ph.D., *The Rockefeller University*

Closing

16:45-17:00 p.m. **Closing Remarks**
Pierre Riviere, Ph.D., *Ferring Pharmaceuticals*





Alain D. Baron, M.D. | Senior Vice President, Research, Amylin Pharmaceuticals

Dr. Baron has been the Senior Vice President, Research since September 2004. He previously served Amylin Pharmaceuticals as the Senior Vice President, Clinical Research and Vice President, Clinical Research. Dr. Baron has been clinical Professor of Medicine at the University of California, San Diego, and Clinical VA Staff Physician at the VA Medical Center, San Diego, since 2001. From 1989 to 2000, Dr. Baron worked for the Indiana University School of Medicine, where he served as Professor of Medicine and Director, Division of Endocrinology and Metabolism. Earlier, Dr. Baron held academic and clinical positions in the Division of Endocrinology and Metabolism at the University of California, San Diego, and the Veterans Administration Medical Center in San Diego. He is the recipient of several prestigious awards for his research in diabetes and vascular disease, including the 1996 Outstanding Clinical Investigator Award from the American Federation for Medical Research, several awards from the American Diabetes Association, and is a current National Institutes of Health MERIT award recipient. He earned his M.D. from the Medical College of Georgia, Augusta, and completed postdoctoral studies at the University of California, San Diego.



Steve Bloom, M.A., M.D., D.Sc., F.R.C.Path., F.R.C.P., F.Med.Sci. | Professor of Medicine

Chairman of Department of Metabolic Medicine, Imperial College

Steve Bloom received his undergraduate medical training at Cambridge University. His house officer, senior house officer and registrar posts were largely undertaken at The Middlesex Hospital where he also received his MRC Clinical Research Fellow training. He moved to the Royal Postgraduate Medical School at Hammersmith Hospital in 1974 where his roles have included senior lecturer (Consultant Physician), Reader in Medicine, Chairman of the Higher Degrees Committee and Academic Board, Professor of Medicine (Hon Consultant Physician), Director of the Endocrinology Clinical Service and Deputy Director, Department of Medicine, Director of Chemical Pathology (renamed Metabolic Medicine), Chief of Clinical Service Chemical Pathology, Chief of Service Endocrinology and Diabetes and Head of the academic Division of Investigative Science, Imperial College London. He now holds a dual role as Chairman of Department of Metabolic Medicine and as Clinical Director for Pathology and Therapy Services at Hammersmith Hospital responsible for a total budget of £40million annually.

His research work over the years falls into five related categories: endocrinology clinical research, physiology and pathology of gut hormones, control of insulin release and insulin resistance, role of neuropeptides in organ control and the role of neuropeptides in CNS regulation of appetite and related hypothalamic functions. He currently leads a research group investigating hypothalamic appetite control systems and gut hormones. This group's discovery that PYY 3-36 reduces appetite offers a potential new treatment for obesity.

He has published over 1000 papers (excluding review articles) in journals such as Nature, J Biol Chem, PNAS, JCI and NEJM. Dr. Bloom is also a Director of Thiakis and has been a member of the main scientific board for AstraZeneca and a member of the advisory boards for Upjohn and Novartis.



Per Cantor, M.D., Ph.D. | Senior VP, Clinical and Non-Clinical Development, Ferring Pharmaceuticals

Per Cantor received his M.D. from the University of Copenhagen, Denmark and received the University's Gold Medal for a study on cholesterol metabolism and atherosclerosis. Along with clinical training at Copenhagen University hospitals, he obtained a fellowship at Rigshospitalet, where he completed a doctoral dissertation on peptide hormones in the gastrointestinal tract. In 1990, he joined Eli Lilly in Denmark as Research Physician and later became Medical Director for Scandinavia. In 2000, he moved to Eli Lilly's corporate center in Indianapolis, USA, as Medical Director of the osteoporosis division with responsibility for global clinical trials. From 2005-6 he was Chief Development Officer in the biotech company Zealand Pharma, and in 2006 he joined FERRING as Senior VP, Clinical and Non-Clinical Development, based in Copenhagen. He has published over 50 papers in international journals and is a frequent speaker on clinical development topics.

**Charles G. Cochrane, M.D. | Professor Emeritus, Department of Immunology,
The Scripps Research Institute**

Charles G. Cochrane is one of the five founding members and serves as professor of Immunology at The Scripps Research Institute. Currently, he holds a position on the board of Discovery Labs as Scientific Advisor. Previously, Dr. Cochrane held faculty positions at The Institut Pasteur, Paris, University of Pittsburgh, School of Medicine, and University of California, School of Medicine. He has published more than 320 scientific papers and is the recipient of many honors and awards for his research in pulmonary disease, including the 2004 Live and Breathe Award from the American Lung Association.

Dr. Cochrane dedicates a large amount of time to many professional organizations. He served as a member of various advisory committees including the National Institute of Health, a member of the editorial board for numerous scientific journals including The Journal of Laboratory and Clinical Medicine, and lecturer for many symposiums and congresses including the Noble Symposium in Stockholm, Sweden.

Dr. Cochrane received his B.A. and M.D. from the University of Rochester. He completed fellowships at the University of Pittsburgh, School of Medicine and the Helen Hay Whitney Research Foundation. Dr. Cochrane started his career in research by studying the mechanisms of inflammatory injury and circulating immune complexes involving leukocytes and platelets. However, his developed understanding and studies of oxidant tissue damage and pulmonary surfactants ultimately lead to the discovery of the synthetic peptide pulmonary KL4 surfactant.

Brad DeHoff, Ph.D. | Technical Manager, Chemistry, Roche Colorado Corporation

Brad DeHoff received his B.A. from Gettysburg College and his Ph.D. from the University of South Carolina in Synthetic Organic Chemistry under Professor James A. Marshall. He continued his studies at the University of Montreal working with Professor Stephen Hanessian on the synthesis of macrolide antibiotics.

Dr. DeHoff is currently the Technical Manager, Chemistry for Roche Colorado supporting the manufacturing and development of peptide APIs.

Prior to his current role, Dr. DeHoff has been the responsible chemist for the process development and clinical supply for some of Roche's small molecules and peptide therapeutics. Included in this job function was an assignment as temporary Roche CMC leader for the Fuzeon project.

**Richard DiMarchi, Ph.D. | Professor & Gill Chair in Biomolecular Science, Indiana University**

Richard DiMarchi is the Linda & Jack Gill Chair in Biomolecular Sciences, and Professor of Chemistry at Indiana University. He is a retired Group Vice President at Eli Lilly & Company where for more than two decades he provided leadership in biotechnology, endocrine research and product development. He is a co-founder of Ambrx, Inc. and Marcadia Biotech. He serves as a board member to Ambrx, Marcadia, Isis Pharmaceuticals, and Alba Therapeutics. He is a scientific advisor to Epitome Biosciences, Kai Pharmaceuticals, Semafore Biotechnologies, and three venture funds: 5AM, TMP, and Twilight.

Professor DiMarchi is readily recognized for discovery and development of rDNA-derived Humalog® (LisPro-human insulin). This designer insulin represents the first demonstration that structurally altered rDNA-derived biosynthetic proteins can improve pharmacological performance without increasing the risk of an abnormal immunological response. As scientist and administrator, Dr. DiMarchi also contributed to the commercial development of Humulin®, Humatrope®, Xigris®, rGlucagon®, Evista®, and Forteo®.

The goal of his current research and commercial endeavors is to develop proteins with enhanced therapeutic properties through biochemical optimization with non-natural amino acids, an approach termed chemical-biotechnology. He recently received the 2005 AAPS Career Research Achievement Award in Biotechnology, the 2006 ACS Earle B. Barnes Award for Leadership in Chemical Research Management, the 2006 ACS Gustavus Esselen Award for Chemistry in the Service of Public Interest, and the 2007 Wallace Carothers Award for Excellence in Polymer Sciences.



Jeffrey M. Friedman, M.D., Ph.D. | Marilyn M. Simpson Professor, The Rockefeller University Investigator, Howard Hughes Medical Institute

Jeffrey Friedman is a physician scientist studying the molecular mechanisms that regulate body weight. In December 1994, he gained worldwide prominence when his research group reported the isolation of the obese (*ob*) gene in mice and humans. In July 1995, his group announced that the *ob* gene is responsible for producing a previously unknown hormone, which he named leptin—from the Greek word leptos, meaning thin. Also found in humans, leptin plays a key role in controlling appetite, energy expenditure, and fat storage.

Dr. Friedman received his B.S. from Rensselaer Polytechnic Institute and his M.D. from Albany Medical College, which named him its 1996 Alumnus of the Year. He completed a residency at Albany Medical Center Hospital and a gastroenterology fellowship at Cornell University Medical College, and then earned a Ph.D. in molecular biology from Rockefeller in 1984. He remained at Rockefeller as a postdoctoral fellow, and in 1986 he was appointed an Assistant Professor and an Assistant Investigator with the Howard Hughes Medical Institute. He became a Tenured Professor and Founding Director of the Starr Center for Human Genetics in 1995, a Howard Hughes Investigator in 1996, and the University's first Marilyn M. Simpson Professor in 1999.

Dr. Friedman received the 2007 Kovalenko Medal for Medical Science from the National Academy of Science and is the recipient of the 2007 Danone International Prize. He received the Passano Foundation Award and a Gairdner Foundation International Award in 2005. Dr. Friedman is also the recipient of the Heinrich Wieland Prize, the University of Goteborg's Jacobaeus Prize, the TOPS Award from the North American Association for the Study of Obesity, the Banting Prize from the British Endocrine Society, the Rolf Luft Award, the Wertheimer Award, the Osborne Mendel Award, the Steven C. Beering Award, the Janssen Award for Special Achievement in Gastroenterology, and the 2001 Bristol-Myers Squibb Award for Distinguished Achievement in Metabolic Research. His work was also listed in Time Magazine Best of Science Section in 1995 and 1996. Dr. Friedman also received the Grand Prize from Popular Science in 1995. He has delivered dozens of named lectures and was elected to the National Academy of Science in 2001 and the Institute of Medicine in 2006.



Michael Hanley, Ph.D. | Vice President, Discovery Research, Amylin Pharmaceuticals

Dr. Hanley has served as Vice President, Discovery Research since October 2003. He has been a member of the scientific advisory board since 1992, and previously served as a senior scientific advisor. Prior to joining Amylin, Dr. Hanley held faculty positions at Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis, where he was Professor of Biological Chemistry. Dr. Hanley has served on advisory or review panels for the National Institutes of Health, the Medical Research Council and Wellcome Trust of Great Britain, and for the governments of Australia, Singapore, New Zealand, Hong Kong, Denmark and Japan. From 1997 to 2003, Dr. Hanley was a senior consultant for healthcare investors in the venture capital and banking communities and for biotechnology companies such as Cell Therapeutics, Zymogenetics, Elan Pharmaceuticals, and Chiron Corporation. Dr. Hanley has also set-up and directed research programs in privately-held start-ups, such as Chemocentryx, PsychoGenics, and most recently Harvard-based Resolvix Pharmaceuticals. He received his B.S. in Biochemistry and his Ph.D. in molecular biology from the University of California, Berkeley.



David Maggs, M.D. | Vice President, Medical Affairs, Amylin Pharmaceuticals

Dr. Maggs has served as Vice President, Medical Affairs since March 2005. He previously served as Executive Director, Medical Affairs, and joined Amylin in October 2000 as our Senior Director, Medical Affairs. Previously, Dr. Maggs served as Director, Medical Research, Diabetes and Metabolism for Parke-Davis Co. Prior to that he was an Assistant Clinical Professor at Yale School of Medicine from 1997 to 1999 and completed fellowships at the University of Nottingham and at Yale School of Medicine. Dr. Maggs completed his original medical training and received his M.B.B.S. and M.R.C.P. degrees from Guys Hospital, University of London and the Royal College of Physicians in London.



Peirre Rivière, Ph.D. | Managing Director & Vice President, Research, Ferring Research Institute, Inc.

Dr. Rivière has served as Managing Director & Vice President, Research, of Ferring Research Institute Inc., in San Diego since January 2006. He joined Ferring in 1996 as Head of Biology and became Director of Research in 2002. In recent years, he contributed to the discovery of five peptidic new chemical entities now at various stages of development. Previously, Dr. Rivière occupied various research and managerial positions in drug discovery at the Institut de Recherche Jouveinal in Fresnes, France. He holds a Ph.D. in biology and physiology from the Institut National Polytechnique of Toulouse, followed by post-doctoral training in the Department of Pharmacology of the University of Arizona in Tucson. Dr. Rivière is scientific co-founder and advisor of Cara Therapeutics.



Thue Schwartz, M.D., D.M.Sci. | Professor of Molecular Pharmacology, University of Copenhagen

Thue Schwartz works part time at 7TM Pharma and in parallel maintains his position as Professor of Molecular Pharmacology at the University of Copenhagen. Previously, he held positions as Research Professor at the Danish Medical Research Council and Research Director in corporate research at Novo Nordisk A/S, where he was leading the departments of computational chemistry, molecular genetics, and molecular pharmacology. Dr. Schwartz has published more than 200 scientific papers (8 of which in Nature or Science) and has received many prizes including the 1990 Jahre Prize, the 1994 Viktor Mutt Award, the 1999 Lundbeck Foundation Prize and the 2001 Novo Nordisk Foundation Prize. Since 1994, he has been a member of the Royal Danish Academy of Sciences. He has served on the board of several biotech companies, including NeuroSearch A/S and Profound Pharma A/S (Maxygen DK from 1999), of which he was co-founder. He has also served on the scientific advisory board of a number of Danish and US biotech companies and is currently a member of the SAB of AnorMED (Langley, BC, Canada).

Dr. Schwartz has been on the advisory board of BankInvest since 1992 and on biotech venture funds of BankInvest since 1997. He is a founder and special advisor of the Nordic Biotech venture funds. He has been on the editorial board of various high-profile scientific journals including Journal of Medicinal Chemistry and Molecular Pharmacology. Dr. Schwartz received his M.D. and D.M.Sci. from the University of Copenhagen.



Andrew A. Young, M.D., Ph.D. | Vice President and Senior Research Fellow, Amylin Pharmaceuticals

Dr. Young has served as Vice President, Research since October 1998 and as Senior Research Fellow since March 2002. From 1989 to 1998, he held a number of positions in Amylin's Physiology Department, including Vice President, Physiology. Prior to joining us in 1989, Dr. Young was a lecturer in the Department of Physiology at the University of Auckland, New Zealand and a part-time general medical practitioner. From 1984 to 1987, Dr. Young was a Clinical Research Scientist at the National Institutes of Health in Phoenix, Arizona, where he studied insulin resistance and diabetes. He received his M.B., Ch.B. (M.D.) and his Ph.D. in Physiology from the University of Auckland, New Zealand.



Hilton La Jolla Torrey Pines

10950 North Torrey Pines Road
La Jolla, California 92037
phone: 1-858-558-1500
fax: 1-858-450-4584

Venue and Accommodations

Be inspired by one of the most exceptional settings in Southern California. Atop the bluffs of La Jolla, California, overlooking the legendary Torrey Pines Golf Course and the majestic Pacific Ocean sits the newly renovated, Four Diamond Hilton La Jolla Torrey Pines hotel. You will experience a feeling of seclusion yet remain close to everything that San Diego, California has to offer.

At the Hilton La Jolla hotel, you can retire to a room rich in comfort. Unique in San Diego, all 394 guestrooms of our Hilton hotel boast a private balcony or patio with magnificent views of the Pacific Ocean, garden or golf course.

The Hilton La Jolla Torrey Pines hotel is conveniently located:

- 15 miles from the San Diego International Airport and downtown San Diego
- Minutes from La Jolla and Del Mar (Del Mar Racetrack)
- Right next to Torrey Pines Golf Course
- Near Birch Aquarium
- Glider Port Park
- Torrey Pines State Reserve
- La Jolla Shores

Directions

From Interstate 5, exit Genesee Avenue and head West. Stay on Genesee and it will curve right and become North Torrey Pines Road. Make a left on Science Park Road (Hilton Hotel Driveway).



List of Attendees • Peptide Therapeutics Symposium

Hilton La Jolla Torrey Pines

November 10, 2007

	First Name	Last Name	Company Name	Job Title	City	Email
	Sudar	Alagarsamy	Ferring	Associate Director	San Diego	sudar.alagarsamy@ferring.com
	James	Aronovsky	Aronovsky Corporate-Photojournalism	Photographer	San Diego	James@Aronovsky.com
	Chris	Bai	AmbioPharm	President & CEO	Carlsbad	chris.bai@ambiopharm.com
Presenter	Alain	Baron	Amylin		San Diego	Alain.Baron@amylin.com
	Channa	Basava	Senn Chemicals	Director, M+S	San Diego	channa.basava@sennchem.com
	Joseph	Bass	Northwestern University	Assistant Professor of Medicine	Evanston	j-bass@northwestern.edu
	Sunil	Bhavsar	Amylin	Medical Science Liaison	San Diego	sunil.bhavsar@amylin.com
Presenter	Steve	Bloom	Hammersmith Hospital		London	s.bloom@imperial.ac.uk
	Simon	Bruce	Amylin	Sr. Med. Director, Clinical Development	San Diego	simon.bruce@amylin.com
	John	Buse	University of North Carolina School of Medicine		Chapel Hill	jbuse@med.unc.edu
Presenter	Per	Cantor	Ferring		Copenhagen	per.cantor@ferring.com
	Hubert	Chen	Amylin	Senior Director Clinical Research	San Diego	hubert.chen@amylin.com
	Ya	Chen	The Burnham Institute for Medical Research	Postdoctoral Associate	La Jolla	ychen@burnhama.org
	Alan	Cherrington	Vanderbilt University		Nashville	alan.cherrington@vanderbilt.edu
Presenter	Charles	Cochrane	The Scripps Research Institute		La Jolla	cochrane@scripps.edu
	Robert	Cogan	The Nath Law Group	Partner	San Diego	rcogan@nathlaw.com
	Glenn	Croston	Ferring	Director In Vitro Pharmacology	San Diego	Glenn.croston@ferring.com
Presenter	Brad	DeHoff	Roche Colorado	Technical Manager	Boulder	brad.dehoff@roche.com
	Ralph	DiLibero	Roche Colorado	Director	Boulder	ralph.dilibero@roche.com
Presenter	Richard	Dimarchi	Indiana University	Professor of Chemistry	Bloomington	rdimarch@indiana.edu
	Xin	Dong	LIAI	Scientific Curator	La Jolla	xdong@liai.org
	Judit	Erchegyi	The Salk Institute	Senior Research Associate	La Jolla	erchegyi@salk.edu
	Gary	Erickson	Roche Colorado	Director	Boulder	Gary_w.erickson@Roche.com
	Robert	Feinstein	Kelaroo, Inc.	VP and CSO	Solana Beach	rdf@kelaroo.com
	Nicky	Ferdyan	Ferring	Research Associate	San Diego	nicky.ferdyan@ferring.com
	Brad	Fikes	North County Times	Journalist	San Diego	bfikes@nctimes.com
	Malcolm	Finlayson	Angstrom Pharmaceuticals	CEO	Solana Beach	mfinlayson@angstrominc.com
	Standish	Fleming	Forward Ventures	Managing Member	San Diego	fleming@forwardventures.com
	Gregory	Fond	Kelaroo, Inc.	Director of Business Development	Solana Beach	gfond@kelaroo.com
Presenter	Jeff	Friedman	The Rockefeller University		New York	friedj@rockefeller.edu
	William	Fuller	Senn Chemicals	Research Director	San Diego	william.fuller@sennchem.com
	Gerald	Galluppi	Biogen Idec	Director, Drug Metab and PK	San Diego	jerry.galluppi@biogenidec.com
	Robert	Galyean	Ferring	Technical Director, Research Chemistry	San Diego	bob.galyean@ferring.com
	Holli	Garrett	CONNECT	Program Director	san diego	hgarrett@connect.org
	Mark	Gergen	Amylin	Senior Vice President, Corporate Development	San Diego	Mark.Gergen@amylin.com
	Soumitra	Ghosh	Amylin	Executive Director Research Chemistry	San Diego	Soumitra.Ghosh@amylin.com
	Robert	Haigh	Ferring Research, UK	Managing Director	Southampton	robert.haigh@ferring.com
Presenter	Michael	Hanley	Amylin	VP Discovery Research	San Diego	michael.hanley@amylin.com
	Chris	Happel	Amylin	Director, Medical Affairs	san Diego	chappel@amylin.com
	Diane	Hargrove	Amylin	Associate Director, Research	San Diego	Diane.Hargrove@amylin.com
	Carey	Harrington	Defense Technology Analysts	CEO	Bonita	carey@dtanalysts.com
	Robert	Henry	UC San Diego, VA Medical Center	Professor	San Diego	rrhenry@ucsd.edu
	Guangcheng	Jiang	Ferring	Research Scientist	San Diego	guangcheng.jiang@ferring.com
	Satish	Joshi	Peptisyntha, Inc	Executive Vice President	Torrance	satish.joshi@solvay.com

	Shima	Joshi	Peptisyntha, Inc.	VP Operations	Torrance	shima.joshi@solvay.com
	Kimon	Kanelakis	Johnson & Johnson	Scientist	San Diego	kkanelak@prdus.jnj.com
	David	Kendall	Amylin	Executive Director, Medical Affairs	San Diego	David.Kendall@amylin.com
	Joy	Koda	Amylin	Sr. Director Clinical Research	San Diego	joy.koda@amylin.com
	Orville	Kolterman	Amylin	Sr. Vice President, Clinical & Regulatory Affairs	San Diego	Orville.Kolterman@amylin.com
	George	Koob	The Scripps Research Institute	Professor and Chair of the Committee On The Neurobiology Of Addictive Disorders	La Jolla	gkoob@scripps.edu
	Daniel	Kosoy	Athenian Venture Partners	Partner	Del Mar	kosoy@athenianvp.com
	Michael	Krupp	Kalos Therapeutics	Chief Business Officer	San Diego	mnkrupp@earthlink.net
	Harold	Lebovitz	SUNY Health Science Center, Brooklin	Professor of Medicine	Staten Island	hlebovitz1@hotmail.com
	Christine	Mack	Amylin	Associate Director	San Diego	cmack@amylin.com
	Derek	Maclean	Kai Pharmaceuticals, Inc.	Director, Chemistry	South San Francisco	derek.maclean@kaipharma.com
Presenter	David	Maggs	Amylin	VP, Medical Affairs	San Diego	David.Maggs@amylin.com
	Rao	Makineni			Rolling Hills	makinenir@aol.com
	Mark	McWilliams	Medipacs	CEO	San Diego	mcwillm@san.rr.com
	Les	Miranda	Amgen Inc.	Director Research	Thousand Oaks	lesm@amgen.com
	Magda	Morton	Johnson & Johnson	Senior Scientist	San Diego	mmorton1@prdus.jnj.com
	Rose	Murphy	UC San Diego	Sr. Licensing Officer	La Jolla	rmmurphy@ucsd.edu
	John	Nestor	Forbes Medi-Tech	Chief Scientific Officer	La Jolla	jnestor@forbesmedi.com
	Philip	Ottiger	Bachem Americas Inc	President & CEO	Torrance	pottiger@usbachem.com
	David	Palella	BioScience Ventures Inc.	President	San Diego	dpalella@san.rr.com
	Norman	Palmer	Stem Cell Partnering Series	Founder & President	La Jolla	n.palmer@stemcellpartnering.org
	Bala	Pandi	AmphiMed	CEO	San Diego	pandi@san.rr.com
	David	Parkes	Amylin	Senior Director In Vivo Pharmacology	San Diego	David.Parkes@amylin.com
	Frederik	Paulsen	Ferring	Chairman		
	David	Pearson	Nidus Laboratories	President and CEO	Los Angeles	niduslabs@gmail.com
	Marilyn	Perrin	The Salk Institute	Scientist	La Jolla	perrin@salk.edu
	Tony	Pietsch	Consultant	Director	Del Mar	tony@tonypietsch.com
	David	Polidori	Johnson & Johnson	Director	San Diego	dpolido1@prdus.jnj.com
	Ken	Polonsky	Washington University School of Medicine	Professor of Medicine, Professor of Cell Biology and Physiology	St. Louis	polonsky@im.wustl.edu
	Charis	Pontis	Process Improvement Consulting		San Diego	cpontis@aol.com
	Daniel	Porte	UC San Diego	Professor	San Diego	dporte@ucsd.edu
	Alex	Rabinovich	Ferring	Senior Chemist	San Diego	aleksandr.rabinovich@ferring.com
	Robert	Ratner	MedStar Research Institute	VP, Scientific Affairs	Hyattsville	ratnermri@aol.com
	Ken	Rind	Caris & Company	Senior Advisor	Del Mar	krind@cariscompany.com
	Jean	Rivier	The Salk Institute	Professor	La Jolla	jrivier@salk.edu
Presenter	Pierre	Riviere	Ferring	Managing Director & Vice President, Research	San Diego	pierre.riviere@ferring.com
	Marvin	Rosenthale		Consultant	Newport Beach	merdrugs@aol.com
	William	Rote	Amylin	Executive Director	San Diego	william.rote@amylin.com
	David	Roth	CODA Genomics	Sr. VP Research and Development	Laguna Hills	droth@codagenomics.com
	Duane	Roth	CONNECT	CEO	La Jolla	djroth@connect.org
	Jane	Salik	PolyPeptide Laboratories	CEO	Torrance	jsalik@pplusa.com
	Arnold	Satterthwait	The Burnham Institute for Medical Research	Associate Professor	La Jolla	asat@burnham.org
	James	Schaeffer	Merck Research Laboratories	Executive Director	La Jolla	jim_schaeffer@merck.com
	Claudio	Schteingart	Ferring	Sr. Director of Chemistry	San Diego	claudio.schteingart@ferring.com
Presenter	Thue	Schwartz	7TM Pharma	Chief Scientific Officer	Copenhagen N.	thue.w.schwartz@molpharm.dk
	Robert	Sherwin	Yale University School of Medicine	Professor of Medicine, Interim Section Chief, Endocrinology	New Haven	robert.Sherwin@yale.edu

	Steven	Smith	Pennington Biomedical Research Center	Professor	Baton Rouge	smithsr@pbrc.edu
	Kent	Smith	Medipacs	Senior Vice President	San Diego	kentsmith@san.rr.com
	Kent	Smith	Medipacs	Senior Vice President	San Diego	kentsmith@san.rr.com
	Chris	Soares	Amylin	Associate Director, Research	San Diego	csoares@amylin.com
	Jacek	Stalewski	Ferring	Associate Director, Chemistry	San Diego	jacek.stalewski@ferring.com
	Cynthia	Stiles	Caris & Company	Vice President	Del Mar	cstiles@cariscompany.com
	Yvette	Tache	UCLA	Professor	Los Angeles	ytache@mednet.ucla.edu
	Habib	Torfi	Invitrx Therapeutics	CEO and President	Mission Viejo	htorfi@invitrx.com
	Jerzy	Trojnar	Ferring	VP Technical Evaluations	San Diego	jerzy.trojnar@ferring.com
	David	Tumelty	CovX Research LLC	Associate Director	San Diego	dtumelty@covx.com
	Michael	Verlander	PolyPeptide Laboratories, Inc.	Executive Vice President	Torrance	mverlander@pplusa.com
	William	Vine	KISS Pharmaceuticals	CEO	San diego	willv@cts.com
	Gordon	Weir	Joslin Diabetes Center	Doctor	Boston	gordon.weir@joslin.harvard.edu
	Christian	Weyer	Amylin	Executive Director Clinical Research	San Diego	christian.weyer@amylin.com
	Richard	White	Ferring	Director	San Diego	richard.white@ferring.com
	Ken	Wilhelm	Amylin	Senior Director Medical Affairs	San Diego	ken.wilhelm@amylin.com
	Karen	Winston	CONNECT	Program Director	La Jolla	kwinston@connect.org
	Kazimierz	Wisniewski	Ferring	Research Scientist	San Diego	Kazimierz.Wisniewski@ferring.com
	Carol	Wysham	Washington State University, Rockwood Clinic	Clinical Assistant Professor of Medicine, Clinical Research Professor, Health Research and Education	Spokane	wysham@wsu.edu
	Tzung	Yang	Asepria	CSO	Carlsbad	thyang@asepria.com
	Christopher	Yea	Ferring Research, UK	Head of Biology	Southampton	chris.yea@ferring.com
	Lynn	Yieh	Johnson & Johnson	Sr. Bioinformaticist	San Diego	lyieh@prdus.jnj.com
	Joe	Young	Amylin	Sr. VP of Marketing	San Diego	joe.young@amylin.com
Presenter	Andrew	Young	Amylin	Vice President, Senior Research Fellow	San Diego	andrew.young@amylin.com
	Andrew	Zelar	Biologics Consulting Group	Sr. Consultant	San Diego	azelar@bcg-usa.com
	Lowell	Zeleznick	POCO Investments llc.	General Manager	Irvine	drzlima@cox.net
	Deshui	Zhang	Ventria Bioscience	Research Scientist	Sacramento	dzhang@ventria.com
	Nicole	Kesty	Amylin		San Diego	Nicole.Kesty@amylin.com
	Michael	Trautmann	Lilly	MD, Research Scientist		